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Diastolic dysfunction of the heart is correlated with cardiac mortality. Serum cystatin C (CysC) is an endogenous 
marker of kidney function. It is not clear whether serum CysC is associated with diastolic dysfunction in patients 
with varying cardiac conditions with concomitant diastolic abnormalities and preserved ejection fraction (EF). 
We measured serum CysC levels in patients with those cardiac diseases and examined the relationships between 
serum CysC levels and diastolic function. We measured serum CysC and performed echocardiography in 124 
consecutive patients with those cardiac diseases. Trans mitral flow (TMF) patterns surrogating diastolic function 
were categorized into 2 groups: a normal group and an abnormal group. Serum CysC and BNP showed a 
significant positive correlation. There were no significant differences in serum CysC among those cardiac 
diseases. Seventy-eight patients with cardiac disease and preserved EF (LVEF ≥ 50%) and without renal 
dysfunction (eGFR ≥ 60mL/min/1.73m2) were examined. Multivariate linear regression analysis demonstrated 
that left atrium diameter and abnormal TMF patterns were independent determinants of serum CysC. 
Furthermore, patients with elevated serum CysC had poor prognosis. Serum CysC is associated with diastolic 
dysfunction in patients with various cardiac diseases and preserved EF. Serum CysC might be a biomarker of 
cardiac diastolic dysfunction in patients with preserved EF. 
 
INTRODUCTION 
Diastolic dysfunction, or heart failure preserved ejection fraction, is independently correlated with cardiac mortality 
[1-4]. However, a diagnostic method has not been established and its diagnosis is often difficult. Therefore, a reliable 
biomarker for its diagnosis is needed.  
Worsening renal function also increases mortality and hospitalization, known as cardio-renal syndrome [5-7]. 
Cystatin C (CysC) is a novel endogenous marker of kidney function that obviates many of the limitations of serum 
creatinine as an endogenous marker of glomerular filtration rate (eGFR) [8-10]. Serum concentrations of CysC 
appear to be unaffected by age, sex, or muscle mass and are more sensitive to mild decrements in GFR than are 
serum concentrations of creatinine. Recently, high CysC concentrations were shown to be associated with increased 
incidence of systolic and diastolic heart failure in a community-based cohort [11] and to be associated with left 
ventricular diastolic dysfunction in patients with coronary artery disease and without heart failure [12] . Therefore, 
serum CysC may be a useful surrogate marker of diastolic dysfunction. However, it is not clear whether serum CysC 
is influenced by disease specificity and whether serum CysC is associated with diastolic dysfunction in patients with 
varying cardiac conditions with concomitant diastolic abnormalities and preserved ejection fraction (EF). We 
therefore measured serum CysC levels in patients with various cardiac diseases and examined the relationships 
between serum CysC levels and diastolic function. 
 
MATERIALS AND METHODS 
Subjects 
We studied consecutive patients with 5 cardiac diseases including coronary artery disease, arrhythmias, 
cardiomyopathy, congenital heart disease, and valvular diseases who had been admitted to Okayama University 
Hospital (Okayama, Japan) during the period from January 2008 to May 2009. We excluded patients with acute 
coronary syndrome and acute heart failure. We measured serum levels of CysC, serum creatinine, thyroid-stimulating 
hormone (TSH), and brain natriuretic peptide (BNP). The patients underwent transthoracic echocardiography at rest 
on the same day. eGFR (mL/min/1.73m
2
) was determined by the modified Modification of Diet and Renal Disease 
study formula (MDRD) for Japanese : eGFR = 194 × (age
-0.287
) × (serum creatinine
-1.094
) × (0.739 if female) [13]. 
Apparent renal dysfunction was defined as eGFR < 60mL/min/1.73m
2
. Informed consent was obtained from all 
patients and this study was approved by our Institutional Review Board. The investigation also conforms to the 
principles outlined in the Declaration of Helsinki. 
Transthoracic echocardiography 
Echocardiographic values were used to determine cardiac function. Echocardiologists were blinded to all of the 
patients’ characteristics including results of blood tests. Echocardiographic studies were performed with Vivid 7 (GE, 
Milwaukee, Wisconsin) as previously described [14]. We obtained standard 2-dimensional parasternal long axis and 
apical 2- and 4-chamber views. Left ventricular diastolic dimension (LVDd), left ventricular systolic dimension 
(LVDs), and left atrium diameter (LAD) were measured by a parasternal long axis view. The ratio of mitral early 
inflow pattern (E) and atrial inflow pattern (A) and the value of early diastolic velocity derived from the septal mitral 
annulus by tissue doppler (E’) were used as surrogates of diastolic function. Trans mitral flow (TMF) patterns were 
categorized into two groups by E/A ratio, mitral E velocity deceleration time (DT) and flow patterns of pulmonary 
veins (PV). A normal TMF pattern (0.75 < E/A ratio < 1.5, DT > 140 msec and dominant systolic PV flow) was 
categorized into the normal group. An impaired relaxation pattern (E/A ratio < 0.75 and dominant systolic PV flow), 
pseudonormalization pattern (0.75 < E/A ratio <1.5, DT > 140 msec and dominant diastolic pulmonary vein flow), 
restrictive pattern (E/A > 1.5, DT < 140 msec, and dominant diastolic pulmonary vein flow) were categorized into an 
abnormal group [2]. We defined LVEF of less than 50% as apparent cardiac systolic dysfunction.  
Laboratory tests 
Serum CysC was measured by an immunologic turbid metric assay (Nescoat GC Cystatin C, Alfresa Pharma, Japan) 
with reference ranges of 0.63 to 0.95 mg/L for men and 0.56 to 0.87 mg/L for women. BNP was measured by a 
standardized and widely validated immunonephelometric method (E-test TOSOH II, TOSOH, Japan) with a 
reference range from less than 18.4 pg/mL. Other laboratory parameters were measured using standard laboratory 
techniques with an automatic analyzer. 
Serum CysC is greatly influenced by thyroid function [15, 16]. We therefore measured TSH levels. If TSH level was 
out of the normal range (< 0.33 μg/mL or > 4.05 μg/mL), we excluded the patients even if the patients had no 
symptoms of thyroid dysfunction. 
Statistical analysis 
Data are expressed as means ± SD. Linear regression analysis was used to evaluate the associations between serum 
CysC, eGFR and echocardiographic values (LVEF, LVDd, LVDs, LAD, E/A ratio, E’, and TMF patterns). The 
Mann-Whitney test and was used to evaluate differences among 2 TMF pattern groups. For comparison between 4 
different TMF groups, statistical analysis was performed using one-way ANOVA with Bonferroni Dunn test. 
Statistical significance was defined as P < 0.05. 
 
RESULTS 
Patients’ characteristics and levels of serum CysC 
One hundred and fifty patients were admitted during the study period. Since serum CysC is influenced by thyroid 
function [15, 16], we excluded 26 patients with thyroid dysfunction; 5 patients had hyperthyroidism (TSH < 0.33 
μg/mL) and 21 patients had hypothyroidism (TSH > 4.05 μg/mL). We evaluated 124 patients w ith cardiac disease 
and with normal thyroid function (Table I).   
We classified all patients into 5 disease groups according to their cardiac disease: coronary artery disease, 
arrhythmias, cardiomyopathy, congenital heart disease, and valvular disease. There were no significant differences in 
serum CysC among the 5 disease groups (P = NS) (Figure 1). Serum CysC and eGFR showed a significant negative 
correlation (r = -0.71, P < 0.001) (Figure 2A), and serum CysC and BNP showed a significant positive correlation (r 
= 0.43, P < 0.001) (Figure 2B). Serum CysC levels were not influenced by disease specificity in this study group.  
Relationships between CysC and echocardiac parameters in patients with cardiac disease 
Results of univariate and multivariate linear regression analyses of relationships between CysC and echocardiac param-
eters are shown in Table II. In univariate analysis, LVDd, LVDs, LVEF, LAD, E/A, E’ and abnormal TMF patterns were 
significantly associated with serum CysC. Moreover, multivariate regression analysis demonstrated that abnormal TMF 
patterns were independently correlative to elevated levels of serum CysC (β = 0.286, P < 0.01). There was a significant 
difference in serum CysC between normal and abnormal groups of TMF patterns (P < 0.001) and there were significant 
differences in serum CysC between patients with normal TMF pattern and patients with impaired relaxation pattern, 
pseudonormalization pattern or restrictive pattern (P < 0.01) (Figure 3). There was no significant difference among ab-
normal TMF groups. 
Relationships between serum CysC and echocardiac parameters in patients with cardiac disease 
    and preserved ejection fraction and without renal dysfunction 
Seventy-eight patients with cardiac disease and preserved ejection fraction (LVEF ≥ 50%) and without renal dysfunc-
tion (eGFR ≥ 60mL/min/1.73m2) were examined (Table III). Table IV shows relationships between serum CysC and 
echocardiac parameters in the 78 patients. In univariate linear regression analysis, LAD, E/A, E’ and TMF patterns, 
surrogates of cardiac diastolic function, were significantly associated with serum CysC. However, LVDd, LVDs and 
LVEF, surrogates of cardiac systolic function, were not associated with serum CysC. Multivariate linear regression 
analysis demonstrated that LAD and abnormal TMF patterns were independent correlates of serum CysC (LAD: β = 
0.362, P < 0.01; abnormal TMF patterns: β = 0.328, P < 0.05). 
Prognostic Significance of Serum Cystatin C 
Serum CysC is also correlated with prognosis in the patients with cardiac diseases. We defined the combined end point 
as all-cause mortality and admission for heart failure. The median follow up period was 24 months (range: 3-36 months). 
In the Kaplan-Meier survival curves (Figure 4), there were significant differences between normal CysC patients and 




The major new findings of this work are that serum CysC was independently correlative to diastolic parameters even in 
the setting of normal kidney function, that serum CysC was not influenced by disease specificity, and that serum CysC 
was associated with diastolic dysfunction in patients with varying cardiac conditions with concomitant diastolic 
abnormalities and preserved ejection fraction and without renal dysfunction.  
CysC is regulated in cardiac remodeling. Cheng et al. reported that CysC mRNA and protein levels are increased in 
hearts of rats and humans with hypertension-induced left ventricular hypertrophy (LVH) [18]. The precise mechanisms 
are not known, but these regulations may be associated with elevation of CysC in patients with diastolic dysfunction.  
Furthermore, patients with elevated serum CysC have poor prognosis. Previous studies showed that CysC was 
associated with the incidence of systolic and diastolic heart failure in a community-based cohort [11] and that CysC was 
associated with more advanced left ventricular diastolic dysfunction in patients with coronary artery disease and without 
heart failure [12] and in patients with chronic systolic heart failure [17]. Our study also suggested that CysC will 
become a surrogate biomarker of cardiac diastolic dysfunction in patients with various cardiac diseases and preserved 
ejection fraction. 
There were no significant differences in serum CysC among various cardiac diseases including coronary artery disease, 
arrhythmias, cardiomyopathy, congenital heart disease, and valvular disease. However, CysC was significantly 
correlated with eGFR and BNP. Therefore, serum CysC may be a common biomarker of cardio-renal dysfunction in 
patients with various cardiac diseases. 
CysC is correlated with abnormal TMF patterns showing cardiac diastolic dysfunction in patients with various cardiac 
diseases and preserved ejection fraction and without renal dysfunction. The mechanism of elevation of CysC in those 
patients remains unclear. Worsening of heart function leads to kidney injury and/or dysfunction [7]. Elevation of CysC 
in those patients may reflect a small change in kidney function due to cardiac dysfunction. Nejat et al. showed that some 
biomarkers of acute kidney injury (AKI) including serum CysC were increased in pre-renal acute injury [19]. Further 
studies are needed to clarify this point.  
In conclusion, serum CysC was shown to be associated with diastolic dysfunction in patients with varying cardiac 
conditions with concomitant diastolic abnormalities and preserved ejection fraction and without renal dysfunction. 
Patients with elevated serum CysC had poor prognosis. These results suggest that serum CysC is a biomarker of cardiac 
diastolic dysfunction in patients with preserved ejection fraction. 
 
STUDY LIMITATIONS 
This study was started in January 2008, and we therefore evaluated diastolic function by using the algorithm in 2003 [2]. 
Further studies are needed to evaluate diastolic function by new algorithms. 
The subjects of this study included subjects with a current smoking habit and subjects using glucocorticoids, which 
have been reported to cause false elevation of serum CysC [20, 21]. Careful assessment is needed to use serum CysC as 
a biomarker of cardiac diastolic function. 
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TABLE I. Patients’ Characteristics 
Number of Patients 124 
Demographics  
 Age, years 62 ± 16 
 Male, n (%) 78 (62) 
 Hypertension, n (%) 71 (57) 
Diabetes Mellitus, n (%) 26 (21) 
Dyslipidemia, n (%) 69 (56) 
Current smoking, n (%) 20 (16) 
Heart failure, n (%) 9 (7) 
NYHA I/II/III/IV 1/5/3/0 
Cardiac diseases  
Coronary artery disease, n (%) 58 (47) 
CSS I/II/III/IV 38/18/2/0 
  OMI, n (%) 11 (19) 
 Arrhythmias, n (%) 39 (31) 
 Cardiomyopathy, n (%) 10 (8) 
 Congenital heart disease, n (%) 10 (8) 
Valvular disease, n (%) 7 (6) 
Medications  
Aspirin, n (%) 43 (35) 
ACEI/ARBs, n (%) 50 (40) 
β-blockers, n (%) 40 (32) 
CCBs, n (%) 36 (29) 
Diuretics, n (%) 33 (27) 
Statins, n (%) 37 (30) 




) 68 ± 21 
 Serum creatinine (mg/dL) 0.84 ± 0.26 
 Serum cystatin C (mg/L) 1.06 ± 0.36 
BNP (pg/mL) 106 ± 192 
Echocardiographic measurements  
 LVEF (%) 64 ± 12 
 LVDd (mm) 48 ± 8 
 LVDs (mm) 31 ± 10 
 LAD (mm) 39 ± 9 
 E/A 1.0 ± 0.5 
 E’ (cm/sec) 6.8 ± 2.8 
Data are shown as the mean ± SD or as number (percentage). eGFR, estimated glomerular fil-
tration rate; BNP, plasma concentration of brain natriuretic peptide; LVEF, left ventricular ejec-
tion fraction; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; 
LAD, left atrium diameter; E/A, ratio of early to late mitral valve flow velocity; E’, early dias-
tolic velocity of the mitral annulus. 
TABLE II. Univariate and multivariate regression analyses for serum CysC in patients with 
 cardiac disease 
Variable 
Univariate Analysis Multivariate Analysis 
r P β P 
LVDd (mm) 0.232 < 0.05 0.013 0.70 
LVDs (mm) 0.269 < 0.01 -0.025 0.63 
EF (%) -0.266 < 0.01 -0.017 0.39 
LAD (mm) 0.274 < 0.01 0.002 0.71 
E/A -0.260 < 0.01 -0.018 0.83 
E’ (cm/sec) -0.286 < 0.01 -0.003 0.87 
TMF patterns 0.410 < 0.001 0.286 < 0.01 
Multivariate analysis included significant factors (P < 0.05) of univariate analysis. LVDd, left 
ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEF, left ventricular 
ejection fraction; LAD, left atrium dimension; E/A, ratio of early to late mitral valve flow ve-
locity; E’, early diastolic velocity of the mitral annulus; TMF patterns, trans mitral flow pat-
terns. 
 
TABLE III. Patients with cardiac disease and preserved ejection fraction and without renal 
dysfunction  
Number of Patients 78 
P values 
(compare with all patients) 
 Age, years 58 ± 17 NS 
 Male, n (%) 52 (67) NS 
 Hypertension, n (%) 36 (46) NS 
 Diabetes mellitus, n (%) 13 (17) NS 
 eGFR (mL/min/1.73m
2
) 84 ± 18 < 0.001 
 Serum creatinine (mg/dL) 0.71 ± 0.13 < 0.001 
 Serum cystatin C (mg/L) 0.88 ± 0.17 < 0.001 
BNP (pg/mL) 53 ± 74 < 0.01 
 LVEF (%) 69 ± 9 < 0.01 
 LVDd (mm) 46 ± 6 < 0.05 
 LVDs (mm) 28 ± 6 < 0.01 
 LAD (mm) 37 ± 8 NS 
 E/A 1.1 ± 0.6 NS 
 E’ (cm/sec) 7.2 ± 3.0 NS 
Data are shown as the mean ± SD or as number (percentage). eGFR, estimated glomerular fil-
tration rate; BNP, plasma concentration of brain natriuretic peptide; LVEF, left ventricular ejec-
tion fraction; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; 
LAD, left atrium diameter; E/A, ratio of early to late mitral valve flow velocity; E’, early dias-
tolic velocity of the mitral annulus; NS, not significant. 
 
 
TABLE IV. Univariate and multivariate regression analyses for serum cystatin C in patients  
without apparent renal and systolic cardiac dysfunction 
Variable 
Univariate Analysis Multivariate Analysis 
r P β P 
LVDd (mm) 0.029 0.80   
LVDs (mm) -0.038 0.74   
EF (%) 0.082 0.48   
LAD (mm) 0.460 < 0.001 0.362 < 0.01 
E/A -0.360 < 0.01 -0.101 0.49 
E’ (cm/sec) -0.441 < 0.001 0.023 0.89 
Abnormal TMF patterns 0.491 < 0.001 0.328 < 0.05 
Multivariate analysis included significant factors (P < 0.05) of univariate analysis. LVDd, left 
ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEF, left ventricular 
ejection fraction; LAD, left atrium dimension; E/A, ratio of early to late mitral valve flow ve-























 Figure 1. Distribution of serum CysC levels among diseases. Patients were classified into 5 
groups by their cardiac disease: coronary artery disease (CAD), arrhythmias, cardiomyopathy 
(CM), congenital heart disease (CHD), and valvular disease (VD). Analysis of variance showed 













 Figure 2. Relationships of serum CysC with eGFR and BNP. A and B show significant correla-
tions between serum CysC and serological markers by regression analysis. A shows a negative 
significant correlation between serum CysC and eGFR (r = -0.71, P < 0.001). B shows a posi-
























 Figure 3. Serum levels of CysC in groups of TMF patterns. Trans mitral flow (TMF) patterns 
surrogating diastolic function were categorized into two groups by E/A ratio, mitral E velocity 
deceleration time and flow patterns of pulmonary veins: a normal group and an abnormal group 
including impaired relaxation, pseudonormalization and restrictive pattern. Serum CysC level 
was significantly higher in the impaired relaxation, pseudonormalization and restrictive pattern 













 Figure 4. All-cause mortality and admission for heart failure between normal CysC patients and 
higher CysC patients. Kaplan-Meier curves for higher CysC patients (Men; > 0.95mg/dL, 
Women; > 0.87mg/dL) and normal CysC patients. Mortality and/or admission for heart failure 
at 3 years 94.5% versus 77.9%. Log rank P < 0.01. 
